drugset / Trial / NCT04408040
Use of Convalescent Plasma for COVID-19
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
Timeline
- Start
- 2020-07-14
- Primary completion
- 2021-09-14
- Completion
- 2021-09-14
Outcome
Outcome not reported
Stopped: “New information regarding use of plasma in covid + patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 200 ml | — |
| Subject | Convalescent Plasma | Protein / enzyme biologic | 425 ml | — |